{
    "clinical_study": {
        "@rank": "90957", 
        "arm_group": {
            "arm_group_label": "Treatment (Melphalan and PBSCT before TBI and Donor PBSCT)", 
            "arm_group_type": "Experimental", 
            "description": "CONDITIONING REGIMEN: Patients receive high-dose melphalan IV over 15-20 minutes on day -2.\nTRANSPLANTATION: Patients undergo autologous bone marrow or PBSCT on day 0.\nNON-MYELOABLATIVE CONDITIONING REGIMEN: Beginning 40-120 days after autologous transplant, patients undergo TBI on day 0.\nTRANSPLANTATION: Patients undergo donor PBSCT on day 0.\nIMMUNOSUPPRESSION: Patients receive cyclosporine IV BID on days -1 and 0 and PO BID on days 1-80 with taper based on evaluation of disease response and GVHD. Patients also receive mycophenolate mofetil PO BID on days 0-27.\nPOST TRANSPLANT DLI: Beginning 4 weeks after immunosuppression, patients achieving persistent or progressive disease may undergo DLI over 30 minutes every 4 weeks for up to 3 treatments."
        }, 
        "brief_summary": {
            "textblock": "In this study donor bone marrow transplantation is divided into a two step process to try to\n      significantly reduce the side effects of the procedure yet still provide patients with\n      multiple myeloma the benefits of this procedure"
        }, 
        "brief_title": "Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma", 
        "condition": [
            "Refractory Multiple Myeloma", 
            "Stage I Multiple Myeloma", 
            "Stage II Multiple Myeloma", 
            "Stage III Multiple Myeloma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To evaluate engraftment of human leukocyte antigen (HLA) identical peripheral blood stem\n      cell (PBSC) allografts given after conditioning with total-body irradiation (TBI) (200 cGy)\n      and post-grafting immunosuppression with cyclosporine (CSP)/mycophenolate mofetil (MMF) in\n      myeloma patients initially cytoreduced with high-dose melphalan.\n\n      II. To evaluate non-relapse mortality at day 100 post allografting. III. To evaluate the\n      efficacy of this allografting strategy in terms of long-term progression free survival\n      (PFS).\n\n      OUTLINE:\n\n      CONDITIONING REGIMEN: Patients receive high-dose melphalan intravenously (IV) over 15-20\n      minutes on day -2.\n\n      TRANSPLANTATION: Patients undergo autologous bone marrow or PBSC transplantation (PBSCT) on\n      day 0.\n\n      NON-MYELOABLATIVE CONDITIONING REGIMEN: Beginning 40-120 days after autologous transplant,\n      patients undergo TBI on day 0.\n\n      TRANSPLANTATION: Patients undergo donor PBSCT on day 0.\n\n      IMMUNOSUPPRESSION: Patients receive cyclosporine IV twice daily (BID) on days -1 and 0 and\n      orally (PO) BID on days 1-80 with taper based on evaluation of disease response and\n      graft-versus-host disease (GVHD). Patients also receive mycophenolate mofetil PO BID on days\n      0-27.\n\n      POST-TRANSPLANTATION DONOR LYMPHOCYTE INFUSION (DLI): Beginning 4 weeks after\n      immunosuppression, patients achieving persistent or progressive disease may undergo DLI over\n      30 minutes every 4 weeks for up to 3 treatments.\n\n      After completion of study treatment, patients are followed up for 3 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Meet Salmon and Durie criteria for initial diagnosis of multiple myeloma; transplant\n             will be offered to patients with stage II or III multiple myeloma (MM) at diagnosis\n             or have received chemotherapy and/or radiation therapy for progressive MM after\n             initial diagnosis of stage I disease\n\n          -  The patient must have the capacity to give informed consent\n\n          -  Have received at least 4 cycles of conventional dose chemotherapy for MM\n\n          -  DONOR: HLA genotypically identical sibling\n\n          -  DONOR: Donor must consent to filgrastim (G-CSF) administration and leukapheresis for\n             both peripheral blood stem cell (PBSC) allograft and subsequent DLI\n\n          -  DONOR: Donor must have adequate veins for leukapheresis or agree to placement of\n             central venous catheter (femoral, subclavian)\n\n          -  DONOR: Age < 75, older donors may be considered after consultation by Psychological\n             Consultation Center (PCC)\n\n        Exclusion Criteria:\n\n          -  Karnofsky score less than 60, unless due solely to myeloma\n\n          -  Left ventricular ejection fraction less than 40%\n\n          -  Bilirubin greater than 2 X the upper limit of normal\n\n          -  Serum glutamic pyruvic transaminase (SGPT) and serum glutamic oxaloacetic\n             transaminase (SGOT) > 2 X the upper limit of normal\n\n          -  Diffusion lung capacity of carbon monoxide (DLCO) < 50% (corrected) or receiving\n             continuous supplemental oxygen\n\n          -  Patients with poorly controlled hypertension\n\n          -  Pregnancy\n\n          -  Seropositive for the human immunodeficiency virus\n\n          -  Fertile men or women unwilling to use contraceptive techniques during and for 12\n             months following treatment\n\n          -  Creatinine clearance < 40 cc/min at the time of initial autografting evaluation\n\n          -  Prior autograft (can be treated on alternative protocol)\n\n          -  DONOR: Identical twin\n\n          -  DONOR: Age less than 12 years\n\n          -  DONOR: Pregnancy\n\n          -  DONOR: Infection with human immunodeficiency virus (HIV)\n\n          -  DONOR: Inability to achieve adequate venous access\n\n          -  DONOR: Known allergy to G-CSF\n\n          -  DONOR: Current serious systemic illness\n\n          -  DONOR: Failure to meet Fred Hutchinson Cancer Research Center (FHCRC) criteria for\n             stem cell donation as described in the standard practice guidelines of the\n             institution"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00003954", 
            "org_study_id": "1383.00", 
            "secondary_id": [
                "NCI-2012-00670", 
                "P01CA078902"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (Melphalan and PBSCT before TBI and Donor PBSCT)", 
                "description": "Given IV", 
                "intervention_name": "melphalan", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Alkeran", 
                    "CB-3025", 
                    "L-PAM", 
                    "L-phenylalanine mustard", 
                    "L-Sarcolysin"
                ]
            }, 
            {
                "arm_group_label": "Treatment (Melphalan and PBSCT before TBI and Donor PBSCT)", 
                "description": "Undergo autologous bone marrow or PBSCT", 
                "intervention_name": "autologous hematopoietic stem cell transplantation", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Treatment (Melphalan and PBSCT before TBI and Donor PBSCT)", 
                "description": "Undergo autologous bone marrow or PBSCT", 
                "intervention_name": "autologous bone marrow transplantation", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "ABMT", 
                    "bone marrow transplantation, autologous", 
                    "transplantation, autologous bone marrow"
                ]
            }, 
            {
                "arm_group_label": "Treatment (Melphalan and PBSCT before TBI and Donor PBSCT)", 
                "description": "Undergo autologous bone marrow or PBSCT", 
                "intervention_name": "peripheral blood stem cell transplantation", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "PBPC transplantation", 
                    "PBSC transplantation", 
                    "peripheral blood progenitor cell transplantation", 
                    "transplantation, peripheral blood stem cell"
                ]
            }, 
            {
                "arm_group_label": "Treatment (Melphalan and PBSCT before TBI and Donor PBSCT)", 
                "description": "Undergo TBI", 
                "intervention_name": "total-body irradiation", 
                "intervention_type": "Radiation", 
                "other_name": "TBI"
            }, 
            {
                "arm_group_label": "Treatment (Melphalan and PBSCT before TBI and Donor PBSCT)", 
                "description": "Undergo donor PBSCT", 
                "intervention_name": "peripheral blood stem cell transplantation", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "PBPC transplantation", 
                    "PBSC transplantation", 
                    "peripheral blood progenitor cell transplantation", 
                    "transplantation, peripheral blood stem cell"
                ]
            }, 
            {
                "arm_group_label": "Treatment (Melphalan and PBSCT before TBI and Donor PBSCT)", 
                "description": "Given IV and PO", 
                "intervention_name": "cyclosporine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "ciclosporin", 
                    "cyclosporin", 
                    "cyclosporin A", 
                    "CYSP", 
                    "Sandimmune"
                ]
            }, 
            {
                "arm_group_label": "Treatment (Melphalan and PBSCT before TBI and Donor PBSCT)", 
                "description": "Given PO", 
                "intervention_name": "mycophenolate mofetil", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Cellcept", 
                    "MMF"
                ]
            }, 
            {
                "arm_group_label": "Treatment (Melphalan and PBSCT before TBI and Donor PBSCT)", 
                "description": "Undergo DLI", 
                "intervention_name": "therapeutic allogeneic lymphocytes", 
                "intervention_type": "Biological", 
                "other_name": "ALLOLYMPH"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclosporins", 
                "Cyclosporine", 
                "Mycophenolic Acid", 
                "Melphalan", 
                "Mycophenolate mofetil"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Duarte", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91010"
                    }, 
                    "name": "City of Hope"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80217"
                    }, 
                    "name": "University of Colorado"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109"
                    }, 
                    "name": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Torino", 
                        "country": "Italy", 
                        "zip": "10126"
                    }, 
                    "name": "University of Torino"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Italy"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Allogeneic Stem Cell Transplantation For Multiple Myeloma: A Two Step Approach To Reduce Toxicity Involving High Dose Melphalan and Autologous Stem Cell Transplant Followed By PBSC Allografting After Low Dose TBI", 
        "overall_official": {
            "affiliation": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium", 
            "last_name": "David Maloney", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2002", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "The current study will be regarded as potentially efficacious if the observed 3-year PFS rate among all patients treated exceeds 30%. The Kaplan-Meier (KM) estimate of PFS will be used.", 
                "measure": "PFS", 
                "safety_issue": "No", 
                "time_frame": "From the date of transplant until the time of progression, relapse, death, or the date the patient was last known to be in remission, up to 3 years"
            }, 
            {
                "measure": "Decrease in the short-term transplant-related mortality", 
                "safety_issue": "No", 
                "time_frame": "Day 100 after allograft"
            }, 
            {
                "measure": "Establish stable allogeneic engraftment (mixed or full donor chimerism)", 
                "safety_issue": "No", 
                "time_frame": "At day 56 after allografting"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00003954"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Estimated by the method of Kaplan and Meier. Confidence intervals will be estimated.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "description": "Summarized using cumulative incidence estimates. Confidence intervals will be estimated.", 
                "measure": "Relapse rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "description": "Confidence intervals will be estimated.", 
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "description": "Confidence intervals will be estimated.", 
                "measure": "Ability to convert mixed to full donor chimerism with DLI", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }
        ], 
        "source": "Fred Hutchinson Cancer Research Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Fred Hutchinson Cancer Research Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 1999", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }, 
    "geocoordinates": {
        "City of Hope": "34.139 -117.977", 
        "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium": "47.606 -122.332", 
        "University of Colorado": "39.739 -104.985", 
        "University of Torino": "45.071 7.684"
    }
}